4.4 Review

Clinical Development of Oncolytic Viruses in China

Journal

CURRENT PHARMACEUTICAL BIOTECHNOLOGY
Volume 13, Issue 9, Pages 1852-1857

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138920112800958760

Keywords

Oncolytic Viruses; cancer; nasopharyngeal carcinoma; GM-CSF; efficacy

Ask authors/readers for more resources

The oncolytic virus, being a promising new therapeutic strategy for cancer, has inspired a wave of recent clinical research and development in China. The first commercialized oncolytic virus, Oncorine, was approved by Chinese SFDA in November 2005 for nasopharyngeal carcinoma combined with chemotherapy. Since then, a number of oncolytic viruses have been moved into clinical trials. Among these are the armed oncolytic adenoviruses such as H103 (expressing the heat shock protein) currently has finished phase I trial, and KH901 (expressing GM-CSF) now launched in phase II trial In this review, we will discuss the current status of ongoing oncolytic virus projects being conducted at various clinical stages in China, including the preliminary market response for Oncorine after it was launched into the Chinese market in 2006.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available